Patricia Ares-Romero, MD, FASAM

Articles by Patricia Ares-Romero, MD, FASAM

Optimizing the Management of TRD

BySteven Levine, MD,Samuel Nordberg, PhD,Martin Rosenzweig, MD,Patricia Ares-Romero, MD, FASAM,Carrie Jardine

May 5th 2022

Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Payer Strategies to Reduce Delay to TRD Therapy

ByCarrie Jardine,Patricia Ares-Romero, MD, FASAM,Martin Rosenzweig, MD,Steven Levine, MD,Samuel Nordberg, PhD

May 5th 2022

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

Integrated Policymaking and Measuring Patient Outcomes in TRD

ByCarrie Jardine,Martin Rosenzweig, MD,Samuel Nordberg, PhD,Patricia Ares-Romero, MD, FASAM,Steven Levine, MD

April 28th 2022

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Navigating Payer Policies for Alternative Therapies in TRD

BySteven Levine, MD,Patricia Ares-Romero, MD, FASAM,Carrie Jardine,Samuel Nordberg, PhD,Martin Rosenzweig, MD

April 28th 2022

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Understanding Billing and Coding for Alternative Therapies in TRD

ByCarrie Jardine,Samuel Nordberg, PhD,Patricia Ares-Romero, MD, FASAM,Martin Rosenzweig, MD,Steven Levine, MD

April 21st 2022

Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.

Benefit Design and Overcoming Barriers to Access for Alternative Therapies in TRD

ByCarrie Jardine,Samuel Nordberg, PhD,Patricia Ares-Romero, MD, FASAM,Martin Rosenzweig, MD,Steven Levine, MD

April 21st 2022

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Risk Evaluation and Mitigation Strategies for Intranasal Esketamine in TRD

ByPatricia Ares-Romero, MD, FASAM,Steven Levine, MD,Martin Rosenzweig, MD,Samuel Nordberg, PhD,Carrie Jardine

April 14th 2022

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Alternative Treatment Options for TRD

ByPatricia Ares-Romero, MD, FASAM,Samuel Nordberg, PhD,Steven Levine, MD,Martin Rosenzweig, MD,Carrie Jardine

April 14th 2022

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Defining Value for TRD Treatment Options

ByPatricia Ares-Romero, MD, FASAM,Steven Levine, MD,Samuel Nordberg, PhD,Carrie Jardine,Martin Rosenzweig, MD

April 7th 2022

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Patient Barriers to Access Treatment for TRD

BySteven Levine, MD,Patricia Ares-Romero, MD, FASAM,Martin Rosenzweig, MD,Samuel Nordberg, PhD,Carrie Jardine

March 31st 2022

Dr Samuel Nordberg and Carrie Jardine discuss barriers to access to care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Risk Factors for TRD and Payer Considerations

BySteven Levine, MD,Martin Rosenzweig, MD,Samuel Nordberg, PhD,Patricia Ares-Romero, MD, FASAM,Carrie Jardine

March 25th 2022

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.